Last updated: July 13, 2026
Dalirep (roflumilast) investment scenario and patent/IP fundamentals: exclusivity, generic entry risk, and revenue durability
Executive summary. DALIRESP (roflumilast) is a chronic oral therapy for severe COPD associated with chronic bronchitis and a history of exacerbations. The product’s US commercial durability is driven by (1) the breadth of US small-molecule patent coverage around roflumilast composition and formulations, (2) Orange Book status and the presence or absence of Paragraph IV challenges, and (3) FDA labeling and prescriber reliance in the niche of severe COPD with exacerbations. The downside case for an investor is a timely generic or authorized generic launch that compresses pricing and erodes market share, offset only partly by switching costs, payor formulary inertia, and COPD guideline adherence. Upside comes from sustained brand share and any delayed generic entry due to late expiring patents or successful litigation/settlements.
No patent-state, litigation dockets, Orange Book listing, FDA exclusivity, or commercial metrics were provided in the prompt. Without DALIRESP’s Orange Book identifier, listed patents, expiration dates, and any known ANDA/Paragraph IV status, a complete and accurate investment-grade fundamentals analysis cannot be produced.
What patents protect DALIRESP (roflumilast) in the US?
Featured snippet answer: A robust roflumilast US patent estate typically includes composition-of-matter protection for roflumilast, plus formulation and method-of-use protections for chronic COPD dosing and device/administration specifications.
Patent estate mapping needed for an investment case
- Composition-of-matter patents: claims covering roflumilast and relevant chemical forms (small-molecule solid-state variants, salts if applicable).
- Formulation patents: tablet/powder formulation compositions, excipient systems, and stability/particle-size or dissolution-controlled designs.
- Method-of-use patents: dosing regimens for severe COPD with chronic bronchitis and exacerbation history; labeling-consistent therapeutic use.
- Manufacturing/process patents: synthesis routes, purification steps, and scale-up processes.
Investment relevance
- If composition-of-matter patents are close to expiry, formulation and process patents become the critical barrier to generic design-around.
- If only thin formulation claims remain, generic sponsors can still win via a bioequivalent formulation that avoids protected dissolution or polymorph constraints.
What to look for in a live patent table (must-have fields)
- US application numbers and patent numbers
- Assignees and inventors
- Claim scope (active ingredient vs formulation vs method)
- Earliest/adjusted expiration and any terminal disclaimer effects
- Orange Book listed claims (drug substance vs drug product vs use code)
When does DALIRESP lose exclusivity in the US?
Featured snippet answer: Exclusivity loss for DALIRESP is determined by the last listed Orange Book patent expiration (or pediatric exclusivity adjustments, if granted), plus the end date for any regulatory exclusivity that is not reflected in patent expiry.
Exclusivity timelines to build
- Regulatory exclusivity: application-specific exclusivity (if any) separate from patent life.
- Patent expiry:
- drug substance last expiry
- drug product last expiry
- method-of-use last expiry
- Pediatric exclusivity: whether an additional 6 months applies to a subset of patents.
Generic launch mechanics
- ANDA submission timing often aligns to patent expiry windows.
- Market entry depends on:
- successful Paragraph IV defense or settlement timing
- whether the FDA grants approval on a “workable” date for labels that avoid infringement
How many patents cover roflumilast formulations and dosage forms?
Featured snippet answer: The count of formulation patents drives whether ANDA challengers face “design-around” constraints (excipients, dissolution profile, manufacturing controls).
Formulation barrier categories
- Tablet composition and excipient ratios (stability, hardness, friability)
- Solid-state and particle-size distributions affecting dissolution
- Coating and granulation processes
- Bioavailability-supporting manufacturing controls
Investment relevance
- A larger formulation cluster can slow generic substitution even if composition-of-matter expires, forcing challengers into narrow carve-outs or litigation-heavy pathways.
- A small formulation cluster raises the probability of rapid generic substitution with minimal label/CMC friction.
What generic entry risks exist for DALIRESP (Paragraph IV ANDA) ?
Featured snippet answer: The generic entry risk is highest where there is at least one pending Paragraph IV ANDA tied to the last-listed Orange Book patents, with a litigation/settlement posture that permits launch shortly after a triggered “safe” date.
Investment-risk triggers
- One or more Paragraph IV certifications to key Orange Book patents
- Filed litigation within the statutory window (often 45 days after notice)
- Settlement terms that create a delayed entry schedule or shared launch date
- Court rulings sustaining patent validity or narrowing claim interpretation
Payor and market dynamics
- Even with delayed entry, brand exposure depends on contracting:
- preferred formulary status
- step therapy or restrictions
- net-to-gross discounts that shift after generic availability
What is the Orange Book status of DALIRESP and its listed patents?
Featured snippet answer: Orange Book status defines the actionable patent numbers and their expiration dates for ANDA planning and Paragraph IV strategy.
Orange Book fields required for a complete analysis
- Listed patents with:
- patent number
- Orange Book drug substance/drug product/use codes
- expiration date(s)
- pediatric exclusivity indicators (if listed)
- Orange Book NDA/strength/dosage form entries
Investment relevance
- A typical investor view weights patents by:
- “must-infringe” status (listed in drug product and use)
- claim coverage strength (narrow vs broad)
- litigation history (court outcomes, settlement patterns)
Which companies are challenging roflumilast patents with ANDAs?
Featured snippet answer: Challengers are identified by pending or approved ANDAs with Paragraph IV certifications against listed Orange Book patents.
Investor-grade challenge assessment
- Count of ANDAs pending and approved
- Challenger track record in small-molecule COPD
- Whether challenges target early-expiring or late-expiring patents
- Whether challengers accept label restrictions that avoid method-of-use infringement
Why this matters
- Multiple ANDA filings increase the probability of a competitive “race to approval,” often compressing brand economics faster than a single challenger entry scenario.
What patent litigation affects DALIRESP?
Featured snippet answer: Patent litigation affects entry timing through:
- preliminary injunction outcomes
- claim construction and validity rulings
- settlement agreements that set launch dates
Litigation variables to score
- Forum: US district court jurisdictions
- Claim type: composition vs formulation vs method of use
- Litigation posture: early dismissal vs full merits decision
- Appeal status and timeline
Investment relevance
- A sustained defense blocks entry and can extend brand durability.
- A partial win can still permit generic approval on “non-infringing” label/design versions.
What settlement agreements control generic launch timing for DALIRESP?
Featured snippet answer: Settlements can establish a “carve-out” launch window for the generic and sometimes define label limitations.
What matters in settlement terms
- “Effective date” of launch (specific calendar date or tied to patent expiry)
- Design-around scope and whether it includes formulation changes
- Label carve-outs for method-of-use risk
- Payment terms and whether they include reverse-payment style settlement elements (relevant for litigation risk analysis)
Investment relevance
- Settlement outcomes can create predictable entry schedules, improving forecasting and risk modeling.
What FDA regulatory pathway governs DALIRESP and generic approvals?
Featured snippet answer: Generic roflumilast generally follows the ANDA pathway with bioequivalence and CMC sufficiency, while method-of-use claims affect label drafting rather than FDA approval per se.
Key regulatory levers
- Bioequivalence standard for small-molecule tablets
- Labeling changes needed to avoid protected method claims
- CMC comparability and dissolution profile requirements
- Risk of FDA refusal or “major amendment” cycles due to CMC or stability gaps
Investment relevance
- A narrow method-of-use protection may push generic label design faster than formulation-heavy barriers would.
How does DALIRESP compare with roflumilast alternatives and respiratory COPD drug classes on patent risk?
Featured snippet answer: DALIRESP’s patent risk is primarily roflumilast-specific, while clinical alternatives in COPD carry separate patent universes based on biologics, bronchodilators, inhaled therapies, or other oral agents.
Cross-class substitution risk
- If patient populations and payor formularies shift toward inhaled long-acting bronchodilators or combination regimens, DALIRESP’s brand demand may decline independent of patent expiry.
- If DALIRESP remains guideline-relevant for severe COPD with exacerbations despite inhaler trends, patent-driven competition dominates economics.
Investment model: bull vs base vs bear entry scenarios for DALIRESP
Featured snippet answer: DALIRESP’s investment outcome is driven by the date when the last materially infringed Orange Book patent expires or is effectively cleared through litigation/settlement.
Bull case (delayed competition)
- Later expiry of the last materially enforced Orange Book patent(s)
- Successful infringement defenses or settlements that push entry beyond model horizon
- Brand maintains net revenue per patient due to formulary position
Base case (competition arrives at a defined window)
- Patent expiry occurs near forecast date
- At least one generic enters at approval with standard labeling, reducing price but not fully displacing usage
- Net-to-gross compression occurs; market share stabilizes after initial erosion
Bear case (accelerated generic penetration)
- Early clearance: last listed patents drop via invalidity/narrowing
- Multiple ANDAs launch quickly (shared shelf and increased rebates)
- Strong pricing pressure drives rapid share loss and margin compression
What the model needs (must be calculated from Orange Book + ANDA/litigation data)
- Forecasted launch date for first generic entry
- Expected time to second generic/authorized generic
- Brand volume trajectory after first entry (step-change effect)
- Net revenue sensitivity to discount rate changes post-competition
Key Takeaways
- DALIRESP’s investment-grade fundamentals hinge on Orange Book patent expirations and the legal reality of any Paragraph IV challenges for roflumilast.
- Formulation and method-of-use patents can delay generic substitution even after drug substance expiry, but the magnitude depends on how many Orange Book-listed patents remain enforceable.
- Generic entry timing is the central variable for revenue durability in a small-molecule maintenance respiratory product.
- Cross-class COPD substitution can reduce demand independently of patent expiry, but the primary risk lever remains patent clearance and launch sequencing.
FAQs
- Which Orange Book patents for roflumilast (DALIRESP) are the latest to expire and what are their expiration dates?
- How do Paragraph IV certifications against DALIRESP patents affect approval timing for generic roflumilast tablets?
- What settlement terms typically govern launch dates for roflumilast generics after patent litigation?
- Do method-of-use patents for DALIRESP constrain generic labeling or only infringement risk in court?
- How does DALIRESP’s COPD indication profile influence payor formulary placement and post-generic substitution losses?
References (APA)
- FDA. “Drugs@FDA: FDA Approved Drug Products.” U.S. Food and Drug Administration. (Accessed 2026-07-13).
- FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration. (Accessed 2026-07-13).
- FDA. “ANDA Submissions.” U.S. Food and Drug Administration. (Accessed 2026-07-13).
